home

From the economic and scientific valorization of patent EP3458607, EMIL has been developed as a novel and advanced diagnostic and prognostic prototype. It provides rapid, user-friendly, reliable, effective, and cost-efficient assessment for patients with Acute Promyelocytic Leukemia (APL).
EMIL is capable of identifying an epigenetic signature associated with resistance to standard therapy and/or with low overall survival (OS) in APL patients.

more…

Epi-C’s goal is to modulate the complex mechanism of epigenetic regulation, forcing cancer cells to restore physiological activity and die either for senescence or programmed death – apoptosis .
In addition, since epigenetic mechanism(s) modulate both the induction and the interference with cell death, Epi-C’s molecules might be applied to degenerative diseases, as well as chronic, metabolic alterations.

Epi-C is a Drug-Agent

specialized in the discovery phase of new molecules

Epi-C (Epigenetic Compounds) is a new spin-off biotech company operating in the field of epigenetics. One of our primary aims is to develop novel drugs with anti-cancer properties.

Epi-C performs small molecule screenings, as well as bio logical and molecular characterisation of drugs.

Epi-C workflow

Epi-C workflow based on library high-throughput screening (HTS)
by automated equipment, data analysis, processing, Hit to lead Identification and Optimization.

Top Italian Scientists (TIS)
EpiGenetics Medicine

Lucia Altucci

MD, PhD

Full Professor of General Pathology, University of Campania Luigi Vanvitelli, IT. She is the scientific director of Epi-C and has more than 20 years of experience and more than 170 scientific publications on epigenetics to his credit.